Compare HYLN & IAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYLN | IAM |
|---|---|---|
| Founded | 2018 | 2019 |
| Country | United States | United States |
| Employees | 113 | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 587.6M | 683.0M |
| IPO Year | 2019 | 2026 |
| Metric | HYLN | IAM |
|---|---|---|
| Price | $3.37 | $14.70 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.75 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 773.8K |
| Earning Date | 11-10-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,475,000.00 | N/A |
| Revenue This Year | $334.53 | N/A |
| Revenue Next Year | $139.40 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 130.28 | N/A |
| 52 Week Low | $1.56 | $13.02 |
| 52 Week High | $8.49 | $24.49 |
| Indicator | HYLN | IAM |
|---|---|---|
| Relative Strength Index (RSI) | 45.54 | 11.23 |
| Support Level | $3.16 | $13.02 |
| Resistance Level | $4.62 | N/A |
| Average True Range (ATR) | 0.18 | 2.60 |
| MACD | -0.02 | -0.77 |
| Stochastic Oscillator | 47.85 | 18.21 |
Hyliion Holdings Corp designs and develops power generators for stationary and mobile applications and provides R&D service. It provides solutions that enable clean, flexible, and affordable electricity production. The company focuses on delivering distributed power generators that can operate on various fuel sources to future-proof against an ever-changing energy economy. In addition to stationary power solutions, it focuses on mobile applications, including vehicles and marine technologies. Its products and services include: KARNO Power Modules which is a modular, fully enclosed, fuel-agnostic and fully integrated power generating solution.
Iambic Therapeutics Inc is a technology and clinical-stage life sciences company developing novel medicines using its proprietary molecular superintelligence platform.